PH23818A - Enhancement of activity of alpha-adrenoceptor antagonists - Google Patents
Enhancement of activity of alpha-adrenoceptor antagonistsInfo
- Publication number
- PH23818A PH23818A PH36022A PH36022A PH23818A PH 23818 A PH23818 A PH 23818A PH 36022 A PH36022 A PH 36022A PH 36022 A PH36022 A PH 36022A PH 23818 A PH23818 A PH 23818A
- Authority
- PH
- Philippines
- Prior art keywords
- enhancement
- adrenoceptor antagonists
- alpha
- activity
- certain
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 title 1
- 108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 title 1
- 239000000496 cardiotonic agent Substances 0.000 abstract 2
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 abstract 1
- 102000015009 alpha1-adrenergic receptor activity proteins Human genes 0.000 abstract 1
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 229940030600 antihypertensive agent Drugs 0.000 abstract 1
- 230000004531 blood pressure lowering effect Effects 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92778586A | 1986-11-05 | 1986-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH23818A true PH23818A (en) | 1989-11-23 |
Family
ID=25455252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH36022A PH23818A (en) | 1986-11-05 | 1987-11-04 | Enhancement of activity of alpha-adrenoceptor antagonists |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0268146B1 (de) |
| JP (1) | JP2612175B2 (de) |
| KR (1) | KR950013758B1 (de) |
| AT (1) | ATE59781T1 (de) |
| DE (1) | DE3767287D1 (de) |
| DK (1) | DK167209B1 (de) |
| ES (1) | ES2036560T3 (de) |
| GR (1) | GR3001375T3 (de) |
| IE (1) | IE59905B1 (de) |
| PH (1) | PH23818A (de) |
| ZA (1) | ZA878182B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ500921A (en) * | 1997-05-19 | 2002-11-26 | Zonagen Inc | Composition containing a-adrenergic antagonist and a phosphodiesterase inhibitor or a dopaminergic agonist for modulating the human sexual response |
| HRP20000407A2 (en) * | 1997-12-16 | 2000-10-31 | Pfizer Prod Inc | Combination effective for the treatment of impotence |
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| EP1579862A1 (de) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Verwendung von PDE III Ihibitoren zur Reduktion der Herzgrösse in an Herzversagen leidenden Säugern |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1920785A1 (de) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Pimobendan-Cyclodextrin Komplex enthaltendes flüssiges Präparat |
| ES2924478T3 (es) | 2012-03-15 | 2022-10-07 | Boehringer Ingelheim Vetmedica Gmbh | Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos |
| US20130274245A1 (en) * | 2012-04-11 | 2013-10-17 | Jan BLUMENSTEIN | Composition For Prevention of Vasoactivity in the Treatment of Blood Loss and Anemia |
| PL3021832T3 (pl) | 2013-07-19 | 2021-08-23 | Boehringer Ingelheim Vetmedica Gmbh | Konserwowana ciekła wodna kompozycja farmaceutyczna zawierająca eteryfikowane pochodne cyklodekstryny |
| BR122019024673B1 (pt) | 2013-12-04 | 2023-04-11 | Boehringer Ingelheim Vetmedica Gmbh | Composições farmacêuticas aprimoradas de pimobendan |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4130647A (en) * | 1977-07-08 | 1978-12-19 | Pfizer Inc. | Methods for treating congestive heart failure and ischemic heart disease |
| US4601897A (en) * | 1985-11-06 | 1986-07-22 | Pfizer Inc. | Prazosin-pirbuterol combination for bronchodilation |
-
1987
- 1987-10-30 ZA ZA878182A patent/ZA878182B/xx unknown
- 1987-11-04 ES ES198787116236T patent/ES2036560T3/es not_active Expired - Lifetime
- 1987-11-04 IE IE297587A patent/IE59905B1/en not_active IP Right Cessation
- 1987-11-04 EP EP87116236A patent/EP0268146B1/de not_active Expired - Lifetime
- 1987-11-04 KR KR1019870012354A patent/KR950013758B1/ko not_active Expired - Lifetime
- 1987-11-04 DE DE8787116236T patent/DE3767287D1/de not_active Expired - Lifetime
- 1987-11-04 AT AT87116236T patent/ATE59781T1/de not_active IP Right Cessation
- 1987-11-04 PH PH36022A patent/PH23818A/en unknown
- 1987-11-04 DK DK578887A patent/DK167209B1/da not_active IP Right Cessation
- 1987-11-05 JP JP62278440A patent/JP2612175B2/ja not_active Expired - Lifetime
-
1991
- 1991-01-24 GR GR91400079T patent/GR3001375T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE3767287D1 (de) | 1991-02-14 |
| DK578887D0 (da) | 1987-11-04 |
| JPS63132837A (ja) | 1988-06-04 |
| ATE59781T1 (de) | 1991-01-15 |
| EP0268146A1 (de) | 1988-05-25 |
| EP0268146B1 (de) | 1991-01-09 |
| IE872975L (en) | 1988-05-05 |
| DK578887A (da) | 1988-05-06 |
| KR950013758B1 (ko) | 1995-11-15 |
| ZA878182B (en) | 1988-05-02 |
| DK167209B1 (da) | 1993-09-20 |
| ES2036560T3 (es) | 1993-06-01 |
| JP2612175B2 (ja) | 1997-05-21 |
| IE59905B1 (en) | 1994-04-20 |
| GR3001375T3 (en) | 1992-09-11 |
| KR880005934A (ko) | 1988-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG17493G (en) | Ozone decontamination of blood and blood products | |
| EG18379A (en) | Novel pharmacological compounds | |
| DE69232485D1 (de) | VERWENDUNG VON RELAXIN zur Herstellung eines Arzneimittels für die Behandlung KARDIOVASKULÄREN Krankeiten. | |
| ES2129423T3 (es) | Vacunas. | |
| GR76810B (de) | ||
| EP0249735A3 (de) | Als aktives Mittel 2-Phenyl-1,2-benzisoselenazol-3(2H)-on enthaltende pharmazeutische Zubereitungen zur Behandlung von durch oxidativen Stress verursachten Krankheiten | |
| PH23818A (en) | Enhancement of activity of alpha-adrenoceptor antagonists | |
| MY106231A (en) | Antiviral tetrahydroimidazo [1,4] benzodiazepin-2- thiones. | |
| NO164904C (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktive griseolsyrederivater. | |
| GR3005870T3 (de) | ||
| EP0319962A3 (de) | Piperidinyl-Methanol-Derivate zur Behandlung von Angstzuständen | |
| ES2014438B3 (es) | Derivados del acido 2-fosfonobutano-1,2,4tricarboxilico, como agentes emulsivos. | |
| ES8704962A1 (es) | Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida. | |
| ES2038642T3 (es) | Tratamiento dermico de enfermedades vermiculares del gato con pracicuantel. | |
| CA1265131C (en) | ERYTHROMYCYLAMINE DERIVATIVES | |
| CA1268468C (en) | PROSTAGLANDIN ANALOGS WITH SUBSTITUTE THIABICYCLOHEPTAN GROUP | |
| EP0248583A3 (en) | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon | |
| UA27973C2 (uk) | Лікарський засіб для лікування серцевої недостатності | |
| ATE126437T1 (de) | Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf. | |
| NO165917C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktivt diamino-2,2-difluorhex-5-yn. | |
| EP0317933A3 (de) | Behandlung von Fibromyalgie | |
| ES2003844A4 (es) | Medio de tratamiento de cabello con un contenido de acido de almandras d,l | |
| ATE69609T1 (de) | Cardiotonische imidazolylphenylpyrrol-2-one. | |
| OA08175A (fr) | Composés contenant un groupe alkylidène-dioxyde, leur préparation et leurs applications thérapeutiques. | |
| GR3008320T3 (de) |